Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

A versatile ultrafast Click platform for antibody based radio diagnostics

Ziel

Diagnosing cancer as early as possible is one of the most powerful strategies in modern medicine to improve
human well-being. Antibodies (Abs) are excellent molecules that can be used to target specific tumors. As Abs
require hours to days for accumulating on tumor surfaces, the use of Abs for nuclear imaging (such as PET
imaging) is limited by the short half-lives of popular radioisotopes. Therefore, we plan to move the step of radiolabeling
from the bench to the tumor itself. However, the entanglement of Abs with an artificial chemical probe is
one of the most promising but at the same time one of the most technically challenging developmental areas in
biotechnology. Our unique approach is based on the production of “hybrid-Abs”, which combine in only one “click”
step the power of synthetic chemistry with the best of biology (“custom-biologics”). Our unique selling points are
ultra-fast, exceptional bioorthogonal and specific labeling reactions in living organism as well as a both-sided
modularity of the connection between Abs and chemical probe. By doing so, high contrast visualization of the
cancer will become possible.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

ERC-POC - Proof of Concept Grant

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2017-PoC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Netto-EU-Beitrag
€ 75 000,00
Adresse
SAARSTRASSE 21
55122 Mainz
Deutschland
Region
Rheinland-Pfalz Rheinhessen-Pfalz Mainz, Kreisfreie Stadt
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 87 500,00

Begünstigte (3)